Trial reportAIDS (London, England)2009
Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents.
Trial report in AIDS (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.
- School functioning of children with perinatal HIV-infection in high-income countries: A systematic review.PloS one · 2021Pooled it
- Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.The Pediatric infectious disease journal · 2015Trial
- Neonatal intrahippocampal HIV-1 protein Tat(1-86) injection: neurobehavioral alterations in the absence of increased inflammatory cytokine activation.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2014Trial
- Glutathione in HIV-Associated Neurocognitive Disorders.Current issues in molecular biology · 2024Review
- CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches.CNS drugs · 2024Review
- Article
- Is HIV Brain Disease Preventable?Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Rapid neurodevelopmental recovery after ART initiation in an infant with HIV encephalopathy.SAGE open medical case reports · 2022Article
- Neuropsychological and Psychosocial Functioning of Children with Perinatal HIV-Infection in The Netherlands.Viruses · 2021Article
- Neurodevelopment in early treated HIV-infected infants participating in a developmental stimulation programme compared with controls.Child: care, health and development · 2021Article
- White matter of perinatally HIV infected older youths shows low frequency fluctuations that may reflect glial cycling.Scientific reports · 2021Article
- Real-World Analysis of Survival and Clinical Events in a Cohort of Italian Perinatally HIV-1 Infected Children From 2001 to 2018.Frontiers in pediatrics · 2021Article
- Neurocognitive Complications of Pediatric HIV Infections.Current topics in behavioral neurosciences · 2021Article
- State of the Mind: Growing up with HIV.Paediatric drugs · 2020Review
- Article
- Educational delays among children living with perinatally-acquired HIV in Johannesburg, South Africa.AIDS care · 2020Article
- Mapping abnormal subcortical neurodevelopment in a cohort of Thai children with HIV.NeuroImage. Clinical · 2019Article
- Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life.Southern African journal of HIV medicine · 2019Article
- Neuroanatomical Changes Underlying Vertical HIV Infection in Adolescents.Frontiers in immunology · 2019Article
- The Association of Home Environment and Caregiver Factors With Neurocognitive Function in Pre-school- and School-Aged Perinatally Acquired HIV-Positive Children on cART in South Africa.Frontiers in pediatrics · 2019Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
objectivesPrior to antiretroviral treatment, HIV-infected children frequently developed encephalopathy, resulting in debilitating morbidity and mortality. This is the first large study to evaluate the impact of HAART and central nervous system (CNS)-penetrating antiretroviral regimens on the incidence of HIV encephalopathy and survival after diagnosis of HIV encephalopathy among perinatally infected children.
designA total of 2398 perinatally HIV-infected children with at least one neurological examination were followed in a US-based prospective cohort study conducted from 1993 to 2007.
methodsTrends in incidence rates over calendar time were described and Cox regression models were used to estimate the effects of time-varying HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy and on survival after diagnosis of HIV encephalopathy.
resultsDuring a median of 6.4 years of follow-up, 77 incident cases of HIV encephalopathy occurred [incidence rate 5.1 cases per 1000 person-years, 95% confidence interval (CI) 4.0-6.3]. A 10-fold decline in incidence was observed beginning in 1996, followed by a stable incidence rate after 2002. HAART regimens were associated with a 50% decrease (95% CI 14-71%) in the incidence of HIV encephalopathy compared with non-HAART regimens. High CNS-penetrating regimens were associated with a substantial survival benefit (74% reduction in the risk of death, 95% CI 39-89%) after HIV encephalopathy diagnosis compared with low CNS-penetrating regimens.
conclusionA dramatic decrease in the incidence of HIV encephalopathy occurred after the introduction of HAART. The use of HAART was highly effective in reducing the incidence of HIV encephalopathy among perinatally infected children and adolescents. Effective CNS-penetrating antiretroviral regimens are important in affecting survival after diagnosis of HIV encephalopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.